- Home
- PRPH vs INDP Comparison
PRPH vs INDP Comparison
Compare PRPH & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- INDP
- Stock Information
- Founded
- PRPH 1989
- INDP 2000
- Country
- PRPH United States
- INDP United States
- Employees
- PRPH N/A
- INDP N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- INDP Health Care
- Exchange
- PRPH Nasdaq
- INDP Nasdaq
- Market Cap
- PRPH 7.8M
- INDP 8.8M
- IPO Year
- PRPH 1997
- INDP N/A
- Fundamental
- Price
- PRPH $0.53
- INDP $0.80
- Analyst Decision
- PRPH Strong Buy
- INDP Strong Buy
- Analyst Count
- PRPH 1
- INDP 2
- Target Price
- PRPH $11.00
- INDP $8.50
- AVG Volume (30 Days)
- PRPH 26.5M
- INDP 28.5K
- Earning Date
- PRPH 03-14-2025
- INDP 03-12-2025
- Dividend Yield
- PRPH N/A
- INDP N/A
- EPS Growth
- PRPH N/A
- INDP N/A
- EPS
- PRPH N/A
- INDP N/A
- Revenue
- PRPH $12,753,000.00
- INDP N/A
- Revenue This Year
- PRPH $36.93
- INDP N/A
- Revenue Next Year
- PRPH $132.05
- INDP N/A
- P/E Ratio
- PRPH N/A
- INDP N/A
- Revenue Growth
- PRPH N/A
- INDP N/A
- 52 Week Low
- PRPH $0.22
- INDP $0.72
- 52 Week High
- PRPH $7.48
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- PRPH 57.09
- INDP 44.62
- Support Level
- PRPH $0.28
- INDP $0.72
- Resistance Level
- PRPH $0.78
- INDP $0.81
- Average True Range (ATR)
- PRPH 0.10
- INDP 0.07
- MACD
- PRPH 0.05
- INDP -0.00
- Stochastic Oscillator
- PRPH 56.07
- INDP 34.43
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.